Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRAF-WORKUP: Gadopiclenol vs Gadobutrol in Renal and Adrenal Findings
NCT07040865Phase 4Terminated
- Sponsor
- Insel Gruppe
- Start
- Aug 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of gadopiclenol in Adrenal incidentaloma (AI) (2 arms), sponsored by Insel Gruppe. Primary endpoint: Enhancement of the kidney and adrenal tissue at 15 months. Started Aug 2025; status: terminated.
02
Drugs
gadopiclenol
03
Conditions
Adrenal incidentaloma (AI)
Beyond the preview
Go deeper on NCT07040865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07040865.